Regeneron Nabs HHS Funding for MERS Therapies

August 24, 2016

Regeneron has inked an agreement with HHS to manufacture and study two antibody therapies for the prevention and treatment of Middle East Respiratory Syndrome.

The agreement with the department’s Biomedical Advanced Research and Development Authority gives Regeneron up to $8.9 million to cover the cost of packaging, labeling and preparing the two antibodies for submission to the FDA as investigational new drugs.

Two of the company’s products—VelociGene and VelocImmune—enabled the discovery and validation of the fully human antibodies specific to the MERS virus.

View today's stories